Transplantation for amyloidosis

被引:63
作者
Gertz, Morie A. [1 ]
Lacy, Martha Q. [1 ]
Dispenzieri, Angela [1 ]
Hayman, Suzanne R. [1 ]
Kumar, Shaji [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Div Hematol, Rochester, MN 55905 USA
关键词
amyloidosis; multiple myeloma; nephrotic syndrome; restrictive cardiomyopathy; stem cell transplantation;
D O I
10.1097/CCO.0b013e32801494c6
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose of review High-dose chemotherapy increasingly is being used for the management of patients with immunoglobulin ligh-chain amyloidosis. We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature. Recent findings We review outcomes, engraftment data, and predictors of early mortality. The survival benefit of transplantation, however, has not been verified in a phase III clinical trial. Summary Partial response rates and complete response rates are prognosticators of survival for patients with amyloidosis. These rates are much higher for patients who receive high-dose therapy and transplantation.
引用
收藏
页码:136 / 141
页数:6
相关论文
共 28 条
[1]
Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? [J].
Bahlis, N. J. ;
Lazarus, H. M. .
BONE MARROW TRANSPLANTATION, 2006, 38 (01) :7-15
[2]
Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience [J].
Chow, LQM ;
Bahlis, N ;
Russell, J ;
Chaudhry, A ;
Morris, D ;
Brown, C ;
Stewart, DA .
BONE MARROW TRANSPLANTATION, 2005, 36 (07) :591-596
[3]
Amyloidosis [J].
Comenzo R.L. .
Current Treatment Options in Oncology, 2006, 7 (3) :225-236
[4]
Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins [J].
Comenzo, RL ;
Zhou, P ;
Fleisher, M ;
Clark, B ;
Teruya-Feldstein, J .
BLOOD, 2006, 107 (09) :3489-3491
[5]
Autologous stem cell transplantation for primary systemic amyloidosis [J].
Comenzo, RL ;
Gertz, MA .
BLOOD, 2002, 99 (12) :4276-4282
[6]
Treatment of AL amyloidosis with high dose therapy and autologous stem cell transplantation [J].
Dimopoulos, Meletios A. .
LEUKEMIA & LYMPHOMA, 2006, 47 (06) :963-964
[7]
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation [J].
Dispenzieri, A ;
Lacy, MQ ;
Katzmann, JA ;
Rajkumar, SV ;
Abraham, RS ;
Hayman, SR ;
Kumar, SK ;
Clark, R ;
Kyle, RA ;
Litzow, MR ;
Inwards, DJ ;
Ansell, SM ;
Micallef, IM ;
Porrata, LF ;
Elliott, MA ;
Johnston, PB ;
Greipp, PR ;
Witzig, TE ;
Zeldenrust, SR ;
Russell, SJ ;
Gastineau, D ;
Gertz, MA .
BLOOD, 2006, 107 (08) :3378-3383
[8]
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival [J].
Dispenzieri, A ;
Lacy, MQ ;
Kyle, RA ;
Therneau, TM ;
Larson, DR ;
Rajkumar, SV ;
Fonseca, R ;
Greipp, PR ;
Witzig, TE ;
Lust, JA ;
Gertz, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3350-3356
[9]
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis [J].
Dispenzieri, A ;
Gertz, MA ;
Kyle, RA ;
Lacy, MQ ;
Burritt, MF ;
Therneau, TM ;
Greipp, PR ;
Witzig, TE ;
Lust, JA ;
Rajkumar, SV ;
Fonseca, R ;
Zeldenrust, SR ;
McGregor, CGA ;
Jaffe, AS .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) :3751-3757
[10]
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study [J].
Dispenzieri, A ;
Kyle, RA ;
Lacy, MQ ;
Therneau, TM ;
Larson, DR ;
Plevak, MF ;
Rajkumar, SV ;
Fonseca, R ;
Greipp, PR ;
Witzig, TE ;
Lust, JA ;
Zeldenrust, SR ;
Snow, DS ;
Hayman, SR ;
Litzow, MR ;
Gastineau, DA ;
Tefferi, A ;
Inwards, DJ ;
Micallef, IN ;
Ansell, SM ;
Porrata, LF ;
Elliott, MA ;
Gertz, MA .
BLOOD, 2004, 103 (10) :3960-3963